MESOBLAST LIMITED - Announcements

Market Cap $1.238B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutioniSe neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University,...

Announcements

Filter Results

All Price Sensitive Only

MSB	Change in substantial holding		10/08/20	230.03KB	Share
MSB	Change in substantial holding		07/08/20	85.81KB	Share
MSB	Appendix 2A		06/08/20	163.17KB	Share
MSB	Proposed issue of Securities - MSB		06/08/20	24.9KB	Share
MSB	COVID-19/GVHD Update, Quarterly Report and Appendix 4C	PRICE SENSITIVE	30/07/20	230.46KB	Share
MSB	Mesoblast Expands Executive Leadership Team		24/07/20	131.59KB	Share
MSB	FDA Advisory Committee Sets Review Date for Remestemcel-L	PRICE SENSITIVE	21/07/20	108.87KB	Share
MSB	Appendix 3B, 2A with prospectus- Kentgrove Capital		07/07/20	809.43KB	Share
MSB	EAP for Remestemcel-L in Children with MIS-C due to COVID-19		06/07/20	108.82KB	Share
MSB	Appendix 2A		30/06/20	163.22KB	Share
MSB	Appendix 3G with 3Ys		24/06/20	267.14KB	Share
MSB	Appendix 2A		16/06/20	166.58KB	Share
MSB	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
MSB	Appendix 2A		01/06/20	164.04KB	Share
MSB	Remestemcel-L Improves Outcomes in Inflammatory Lung Disease	PRICE SENSITIVE	01/06/20	116.33KB	Share
MSB	MSB Reports Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	28/05/20	281.8KB	Share
MSB	Third Quarter Results Presentation		28/05/20	1.72MB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	28/05/20	614.49KB	Share
MSB	Change in substantial holding		27/05/20	250.69KB	Share
MSB	3 Articles on RYONCIL GvHD Trial Results Published in BBMT		25/05/20	124.22KB	Share
MSB	Change in substantial holding		19/05/20	159.15KB	Share
MSB	Cleansing Notice		18/05/20	72.61KB	Share
MSB	Appendix 2As		15/05/20	375.44KB	Share
MSB	Proposed issue of Securities - MSB		13/05/20	27.78KB	Share
MSB	MSB Completes Financing For Covid-19 ARDS Manufacturing	PRICE SENSITIVE	13/05/20	144.68KB	Share
MSB	Trading Halt	PRICE SENSITIVE	11/05/20	170.3KB	Share
MSB	First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS		06/05/20	128.22KB	Share
MSB	Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment	PRICE SENSITIVE	30/04/20	140.07KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/20	193.38KB	Share
MSB	83% Survival in COVID-19 ARDS Patients with Remestemcel-L	PRICE SENSITIVE	24/04/20	144.87KB	Share
MSB	Inflammatory Lung Disease Outcomes For Presentation at ISCT		17/04/20	116.14KB	Share
MSB	US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial	PRICE SENSITIVE	09/04/20	95.91KB	Share
MSB	FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients	PRICE SENSITIVE	06/04/20	89.95KB	Share
MSB	FDA Accepts BLA for RYONCIL and Agrees to Priority Review	PRICE SENSITIVE	01/04/20	92.3KB	Share
MSB	Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting		30/03/20	94.18KB	Share
MSB	Change of Director's Interest Notice		20/03/20	71.77KB	Share
MSB	Appendix 2A		17/03/20	147.18KB	Share
MSB	Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease	PRICE SENSITIVE	10/03/20	98.41KB	Share
MSB	Mesoblast Provides Half Year Results and Corporate Update	PRICE SENSITIVE	27/02/20	223.76KB	Share
MSB	Half Year Financial Results Presentation		27/02/20	1.46MB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	27/02/20	757.72KB	Share
MSB	Mesoblast Half Year FY 2020 Financial Results Analyst Call		25/02/20	70.25KB	Share
MSB	Ryoncil Results in Children with Acute GvHD Presented at TCT		24/02/20	146.94KB	Share
MSB	Appendix 3G		21/02/20	131.61KB	Share
MSB	Positive Outcomes Using Remestemcel-L in Chronic GVHD		20/02/20	94.61KB	Share
MSB	Appendix 2A		07/02/20	165.97KB	Share
MSB	Mesoblast Submits Completed BLA for Ryoncil to US FDA	PRICE SENSITIVE	03/02/20	114.77KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/20	219.65KB	Share
MSB	Appendix 2A		24/01/20	147.69KB	Share
MSB	Biotech Showcase Presentation		15/01/20	2.05MB	Share
MSB	MSB Presents Commercial Plans at 2020 Biotech Showcase		15/01/20	144.16KB	Share
MSB	Appendix 2A		02/01/20	143.67KB	Share
MSB	MSB Files GvHD Clinical Efficacy and Safety Data with US FDA	PRICE SENSITIVE	02/01/20	128.07KB	Share
MSB	DMC Completes Final Review of Phase 3 Heart Failure Trial	PRICE SENSITIVE	18/12/19	119.18KB	Share
MSB	CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)	PRICE SENSITIVE	17/12/19	122.93KB	Share
MSB	CHF P3 Trial Accrues Sufficient Primary Endpoint Events	PRICE SENSITIVE	17/12/19	122.57KB	Share
MSB	Ceasing to be a substantial holder		05/12/19	212.21KB	Share
MSB	Change of Director's Interest Notice		05/12/19	70.89KB	Share
MSB	Results of Meeting		27/11/19	183.19KB	Share
MSB	Mesoblast Chairman Message to 2019 AGM		27/11/19	105.21KB	Share
MSB	Presentation to 2019 Annual General Meeting		27/11/19	1.64MB	Share
MSB	MSB Provides Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	26/11/19	309.78KB	Share
MSB	First Quarter Results Presentation		26/11/19	1.67MB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	26/11/19	502.82KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	212.78KB	Share
MSB	Annual Report to shareholders		29/10/19	5.08MB	Share
MSB	Notice of General Meeting/Proxy Form		29/10/19	304.7KB	Share
MSB	Appendix 4G and Corporate Governance Statement		29/10/19	242KB	Share
MSB	Appointment of Joint Company Secretary		29/10/19	92.31KB	Share
MSB	Ceasing to be a substantial holder		23/10/19	41.85KB	Share
MSB	Change in substantial holding		23/10/19	85.89KB	Share
MSB	Change in substantial holding		23/10/19	231.98KB	Share
MSB	MSB and Lonza Enter GVHD Commercial Manufacturing Agreement	PRICE SENSITIVE	17/10/19	94.01KB	Share
MSB	Change in substantial holding		10/10/19	526.49KB	Share
MSB	Cleansing notice and Appendix 3B		08/10/19	197.29KB	Share
MSB	Change in substantial holding		08/10/19	71.35KB	Share
MSB	Mesoblast Raises A$75 Million	PRICE SENSITIVE	03/10/19	112.24KB	Share
MSB	Trading Halt	PRICE SENSITIVE	01/10/19	288.32KB	Share
MSB	Release of Shares from Voluntary Escrow		27/09/19	86.42KB	Share
MSB	Mesoblast Newsletter - Chronic Low Back Pain		27/09/19	575.08KB	Share
MSB	Analyst Call Presentation		10/09/19	1.7MB	Share
MSB	Analyst Call Details		10/09/19	83.18KB	Share
MSB	Grunenthal and MSB Enter Strategic Partnership for Back Pain	PRICE SENSITIVE	10/09/19	127.73KB	Share
MSB	Mesoblast Reports on Annual Results	PRICE SENSITIVE	30/08/19	243.33KB	Share
MSB	Annual Financial Results Presentation		30/08/19	4.48MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	30/08/19	3.68MB	Share
MSB	FDA Guidance on Clinical Pathway for LVAD Market Application	PRICE SENSITIVE	27/08/19	108.18KB	Share
MSB	Investigator-Initiated Trial Planned for Chronic GVHD		14/08/19	73.45KB	Share
MSB	Mesoblast Appoints Leading Pharma Industry Executive as CMO		12/08/19	72.69KB	Share
MSB	Appendix 4C - Quarterly, Strong Commercialization Revenues	PRICE SENSITIVE	31/07/19	198.68KB	Share
MSB	Circulation Research Highlights MSB Heart Failure Therapy	PRICE SENSITIVE	25/07/19	125.8KB	Share
MSB	Newsletter - Interview with GvHD Key Opinion Leader		15/07/19	931.81KB	Share
MSB	Change in substantial holding		12/07/19	77.12KB	Share
MSB	Appendix 3B		11/07/19	113.03KB	Share
MSB	Release of Shares from Voluntary Escrow		26/06/19	86.12KB	Share
MSB	FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs	PRICE SENSITIVE	24/06/19	134.93KB	Share
MSB	High Economic Burden In Steroid-Refractory aGVHD		18/06/19	94.6KB	Share
MSB	MSB to Host Virtual Symposium with KOL on GvHD		17/06/19	92.26KB	Share
MSB	MSB Expands JCR Partnership To Brain Disease In Newborns	PRICE SENSITIVE	11/06/19	94.26KB	Share
MSB	MSB Provides Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	31/05/19	184.53KB	Share

MSB Change in substantial holding
10/08/20		230.03KB	Share
MSB Change in substantial holding
07/08/20		85.81KB	Share
MSB Appendix 2A
06/08/20		163.17KB	Share
MSB Proposed issue of Securities - MSB
06/08/20		24.9KB	Share
MSB COVID-19/GVHD Update, Quarterly Report and Appendix 4C
30/07/20	PRICE SENSITIVE	230.46KB	Share
MSB Mesoblast Expands Executive Leadership Team
24/07/20		131.59KB	Share
MSB FDA Advisory Committee Sets Review Date for Remestemcel-L
21/07/20	PRICE SENSITIVE	108.87KB	Share
MSB Appendix 3B, 2A with prospectus- Kentgrove Capital
07/07/20		809.43KB	Share
MSB EAP for Remestemcel-L in Children with MIS-C due to COVID-19
06/07/20		108.82KB	Share
MSB Appendix 2A
30/06/20		163.22KB	Share
MSB Appendix 3G with 3Ys
24/06/20		267.14KB	Share
MSB Appendix 2A
16/06/20		166.58KB	Share
MSB S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
MSB Appendix 2A
01/06/20		164.04KB	Share
MSB Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
01/06/20	PRICE SENSITIVE	116.33KB	Share
MSB MSB Reports Q3 Financial Results and Operational Highlights
28/05/20	PRICE SENSITIVE	281.8KB	Share
MSB Third Quarter Results Presentation
28/05/20		1.72MB	Share
MSB Third Quarter Financial Results on Form 6-K
28/05/20	PRICE SENSITIVE	614.49KB	Share
MSB Change in substantial holding
27/05/20		250.69KB	Share
MSB 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
25/05/20		124.22KB	Share
MSB Change in substantial holding
19/05/20		159.15KB	Share
MSB Cleansing Notice
18/05/20		72.61KB	Share
MSB Appendix 2As
15/05/20		375.44KB	Share
MSB Proposed issue of Securities - MSB
13/05/20		27.78KB	Share
MSB MSB Completes Financing For Covid-19 ARDS Manufacturing
13/05/20	PRICE SENSITIVE	144.68KB	Share
MSB Trading Halt
11/05/20	PRICE SENSITIVE	170.3KB	Share
MSB First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS
06/05/20		128.22KB	Share
MSB Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
30/04/20	PRICE SENSITIVE	140.07KB	Share
MSB Appendix 4C - quarterly
29/04/20	PRICE SENSITIVE	193.38KB	Share
MSB 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
24/04/20	PRICE SENSITIVE	144.87KB	Share
MSB Inflammatory Lung Disease Outcomes For Presentation at ISCT
17/04/20		116.14KB	Share
MSB US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
09/04/20	PRICE SENSITIVE	95.91KB	Share
MSB FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
06/04/20	PRICE SENSITIVE	89.95KB	Share
MSB FDA Accepts BLA for RYONCIL and Agrees to Priority Review
01/04/20	PRICE SENSITIVE	92.3KB	Share
MSB Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
30/03/20		94.18KB	Share
MSB Change of Director's Interest Notice
20/03/20		71.77KB	Share
MSB Appendix 2A
17/03/20		147.18KB	Share
MSB Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
10/03/20	PRICE SENSITIVE	98.41KB	Share
MSB Mesoblast Provides Half Year Results and Corporate Update
27/02/20	PRICE SENSITIVE	223.76KB	Share
MSB Half Year Financial Results Presentation
27/02/20		1.46MB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
27/02/20	PRICE SENSITIVE	757.72KB	Share
MSB Mesoblast Half Year FY 2020 Financial Results Analyst Call
25/02/20		70.25KB	Share
MSB Ryoncil Results in Children with Acute GvHD Presented at TCT
24/02/20		146.94KB	Share
MSB Appendix 3G
21/02/20		131.61KB	Share
MSB Positive Outcomes Using Remestemcel-L in Chronic GVHD
20/02/20		94.61KB	Share
MSB Appendix 2A
07/02/20		165.97KB	Share
MSB Mesoblast Submits Completed BLA for Ryoncil to US FDA
03/02/20	PRICE SENSITIVE	114.77KB	Share
MSB Appendix 4C - quarterly
29/01/20	PRICE SENSITIVE	219.65KB	Share
MSB Appendix 2A
24/01/20		147.69KB	Share
MSB Biotech Showcase Presentation
15/01/20		2.05MB	Share
MSB MSB Presents Commercial Plans at 2020 Biotech Showcase
15/01/20		144.16KB	Share
MSB Appendix 2A
02/01/20		143.67KB	Share
MSB MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
02/01/20	PRICE SENSITIVE	128.07KB	Share
MSB DMC Completes Final Review of Phase 3 Heart Failure Trial
18/12/19	PRICE SENSITIVE	119.18KB	Share
MSB CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
17/12/19	PRICE SENSITIVE	122.93KB	Share
MSB CHF P3 Trial Accrues Sufficient Primary Endpoint Events
17/12/19	PRICE SENSITIVE	122.57KB	Share
MSB Ceasing to be a substantial holder
05/12/19		212.21KB	Share
MSB Change of Director's Interest Notice
05/12/19		70.89KB	Share
MSB Results of Meeting
27/11/19		183.19KB	Share
MSB Mesoblast Chairman Message to 2019 AGM
27/11/19		105.21KB	Share
MSB Presentation to 2019 Annual General Meeting
27/11/19		1.64MB	Share
MSB MSB Provides Q1 Financial Results and Operational Highlights
26/11/19	PRICE SENSITIVE	309.78KB	Share
MSB First Quarter Results Presentation
26/11/19		1.67MB	Share
MSB First Quarter Financial Results on Form 6-K
26/11/19	PRICE SENSITIVE	502.82KB	Share
MSB Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	212.78KB	Share
MSB Annual Report to shareholders
29/10/19		5.08MB	Share
MSB Notice of General Meeting/Proxy Form
29/10/19		304.7KB	Share
MSB Appendix 4G and Corporate Governance Statement
29/10/19		242KB	Share
MSB Appointment of Joint Company Secretary
29/10/19		92.31KB	Share
MSB Ceasing to be a substantial holder
23/10/19		41.85KB	Share
MSB Change in substantial holding
23/10/19		85.89KB	Share
MSB Change in substantial holding
23/10/19		231.98KB	Share
MSB MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
17/10/19	PRICE SENSITIVE	94.01KB	Share
MSB Change in substantial holding
10/10/19		526.49KB	Share
MSB Cleansing notice and Appendix 3B
08/10/19		197.29KB	Share
MSB Change in substantial holding
08/10/19		71.35KB	Share
MSB Mesoblast Raises A$75 Million
03/10/19	PRICE SENSITIVE	112.24KB	Share
MSB Trading Halt
01/10/19	PRICE SENSITIVE	288.32KB	Share
MSB Release of Shares from Voluntary Escrow
27/09/19		86.42KB	Share
MSB Mesoblast Newsletter - Chronic Low Back Pain
27/09/19		575.08KB	Share
MSB Analyst Call Presentation
10/09/19		1.7MB	Share
MSB Analyst Call Details
10/09/19		83.18KB	Share
MSB Grunenthal and MSB Enter Strategic Partnership for Back Pain
10/09/19	PRICE SENSITIVE	127.73KB	Share
MSB Mesoblast Reports on Annual Results
30/08/19	PRICE SENSITIVE	243.33KB	Share
MSB Annual Financial Results Presentation
30/08/19		4.48MB	Share
MSB Preliminary Final Report including Appendix 4E
30/08/19	PRICE SENSITIVE	3.68MB	Share
MSB FDA Guidance on Clinical Pathway for LVAD Market Application
27/08/19	PRICE SENSITIVE	108.18KB	Share
MSB Investigator-Initiated Trial Planned for Chronic GVHD
14/08/19		73.45KB	Share
MSB Mesoblast Appoints Leading Pharma Industry Executive as CMO
12/08/19		72.69KB	Share
MSB Appendix 4C - Quarterly, Strong Commercialization Revenues
31/07/19	PRICE SENSITIVE	198.68KB	Share
MSB Circulation Research Highlights MSB Heart Failure Therapy
25/07/19	PRICE SENSITIVE	125.8KB	Share
MSB Newsletter - Interview with GvHD Key Opinion Leader
15/07/19		931.81KB	Share
MSB Change in substantial holding
12/07/19		77.12KB	Share
MSB Appendix 3B
11/07/19		113.03KB	Share
MSB Release of Shares from Voluntary Escrow
26/06/19		86.12KB	Share
MSB FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
24/06/19	PRICE SENSITIVE	134.93KB	Share
MSB High Economic Burden In Steroid-Refractory aGVHD
18/06/19		94.6KB	Share
MSB MSB to Host Virtual Symposium with KOL on GvHD
17/06/19		92.26KB	Share
MSB MSB Expands JCR Partnership To Brain Disease In Newborns
11/06/19	PRICE SENSITIVE	94.26KB	Share
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/19	PRICE SENSITIVE	184.53KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last $1.09		Change 0.015(1.40%)		Mkt cap ! $1.238B

Open	High	Low	Value	Volume
$1.11	$1.12	$1.08	$11.51M	10.52M

Buyers (Bids)

No.	Vol.	Price($)
2	17804	$1.09

Sellers (Offers)

Price($)	Vol.	No.
$1.09	230637	5

View Market Depth

No.	Vol.	Price($)
1	2500	1.085
8	103868	1.080
4	20400	1.075
11	85089	1.070
4	50577	1.065

Price($)	Vol.	No.
1.090	5437	2
1.095	19582	2
1.100	34717	4
1.105	10000	1
1.110	53313	3

Last trade - 16.10pm 03/05/2024 (20 minute delay)


Last $1.09		Change 0.015 ( 1.85 %)
Open	High	Low	Volume
$1.10	$1.12	$1.08	1937390
Last updated 15.59pm 03/05/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories